A detailed history of Jpmorgan Chase & CO transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,275,859 shares of KPTI stock, worth $1.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,275,859
Previous 1,377,584 7.38%
Holding current value
$1.19 Million
Previous $2.08 Million 46.68%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$0.87 - $1.58 $88,500 - $160,725
-101,725 Reduced 7.38%
1,275,859 $1.11 Million
Q1 2024

May 10, 2024

BUY
$0.72 - $1.66 $141,454 - $326,130
196,464 Added 16.63%
1,377,584 $2.08 Million
Q4 2023

Feb 12, 2024

BUY
$0.68 - $1.31 $27,195 - $52,392
39,994 Added 3.5%
1,181,120 $1.02 Million
Q3 2023

Nov 14, 2023

BUY
$1.14 - $1.81 $1.2 Million - $1.9 Million
1,051,695 Added 1175.98%
1,141,126 $1.53 Million
Q2 2023

Aug 11, 2023

SELL
$1.79 - $4.59 $181,214 - $464,677
-101,237 Reduced 53.1%
89,431 $160,000
Q1 2023

May 18, 2023

BUY
$2.84 - $3.92 $169,383 - $233,796
59,642 Added 45.52%
190,668 $741,000
Q1 2023

May 11, 2023

SELL
$2.84 - $3.92 $3.84 Million - $5.3 Million
-1,351,138 Reduced 91.16%
131,026 $509,000
Q4 2022

Feb 13, 2023

BUY
$2.48 - $5.93 $3.23 Million - $7.73 Million
1,302,937 Added 726.98%
1,482,164 $5.04 Million
Q3 2022

Nov 14, 2022

SELL
$4.08 - $5.82 $20,147 - $28,739
-4,938 Reduced 2.68%
179,227 $978,000
Q2 2022

Aug 11, 2022

SELL
$4.15 - $8.37 $2.22 Million - $4.47 Million
-534,475 Reduced 74.37%
184,165 $830,000
Q1 2022

May 11, 2022

SELL
$5.91 - $14.38 $146,331 - $356,048
-24,760 Reduced 3.33%
718,640 $5.3 Million
Q4 2021

Feb 10, 2022

BUY
$5.21 - $8.61 $1.45 Million - $2.4 Million
278,479 Added 59.9%
743,400 $4.78 Million
Q3 2021

Nov 12, 2021

BUY
$4.45 - $10.63 $2.07 Million - $4.94 Million
464,921 New
464,921 $2.71 Million

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $74.2M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.